Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.69 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.56 |
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27859507 | 1.00 | HDAC8 (0.69) | HDAC8HDAC1PDE4BMAPTHDAC3 | |
| SCHEMBL7923588 | 0.98 | PDE4B (0.70) | HDAC8HDAC1PDE4BMAPTHDAC3 | |
| SCHEMBL7995333 | 0.95 | PDE4B (0.75) | HDAC8HDAC1PDE4BMAPTHDAC3 | |
| SCHEMBL3171960 | 0.91 | PDE4B (0.79) | HDAC8HDAC1PDE4BMAPTHDAC3 | |
| SCHEMBL6820048 | 0.89 | MMP1 (0.65) | HDAC8HDAC1PDE4BMAPTHDAC3 | |
| SCHEMBL13493042 | 0.89 | HDAC8 (0.64) | HDAC8HDAC1PDE4BMAPTHDAC3 | |
| SCHEMBL4082864 | 0.87 | PDE4B (0.86) | HDAC8HDAC1PDE4BMAPTHDAC3 | |
| SCHEMBL9809353 | 0.86 | HDAC8 (0.69) | HDAC8HDAC1PDE4BMAPTHDAC3 | |
| SCHEMBL3104200 | 0.86 | PDE4B (0.90) | HDAC8HDAC1PDE4BMAPTHDAC3 | |
| SCHEMBL10793133 | 0.86 | PDE4B (0.68) | HDAC8HDAC1PDE4BMAPTHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550965-B1 | Ceramide derivatives for treating polycystic kidney disease | GENZYME CORP (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-2209473-B1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORP (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2320886-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORP (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2167485-B1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2015-09-30 | — | — | EP | disclosed |
| US-8729075-B2 | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease | GENZYME CORPORATION (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130225573-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2594565-A2 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | Genzyme Corporation (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594563-A2 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | Genzyme Corporation (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594564-A2 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | Genzyme Corporation (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594562-A2 | 2-acylaminopropanol-type glucosylceramide synthase inhibitors | Genzyme Corporation (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2550965-A2 | Ceramide derivatives for treating polycystic kidney disease | GENZYME CORPORATION (US) | 2013-01-30 | — | — | EP | disclosed |
| US-8304447-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100256216-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2010-10-07 | — | — | US | disclosed |
| WO-2010014554-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORPORATION (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2009117150-A2 | METHOD OF TREATING LUPUS WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2008150486-A2 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256216-A1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | ASAH2, GBA1, GAA | HDAC8 2009/4885HDAC1 885/4885PDE4B 1462/4885 |
| US-20130225573-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GBA1, UGCG, GBA2 | HDAC8 2106/4885HDAC1 1853/4885PDE4B 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.